0000000000179235

AUTHOR

Michiel Coppens

showing 6 related works from this author

Safety of prothrombin complex concentrate in healthy subjects

2017

Keywords: anticoagulants; prothrombin complex concentrate; thrombosis; reversal; meta-analysis; bleeding disorders

0301 basic medicinemedicine.medical_specialtybusiness.industryHealthy subjectsHemorrhageHematology030204 cardiovascular system & hematologymedicine.diseaseThrombosisProthrombin complex concentrateBlood Coagulation FactorsHealthy Volunteers03 medical and health sciences030104 developmental biology0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineHumansbusinessBlood Coagulationhuman activitiescirculatory and respiratory physiologymedicine.drug
researchProduct

Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline

2016

AdultVenous ThrombosisParenteral Nutritionmedicine.medical_specialtyNutrition and DieteticsAdult patientsbusiness.industryAnticoagulantsVenous ThromboembolismGuideline030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicinemedicine.diseaseThrombosis03 medical and health sciencesVenous thrombosis0302 clinical medicineParenteral nutritionmedicineHumans030211 gastroenterology & hepatologyParenteral Nutrition HomeIntensive care medicinebusinessVenous thromboembolism
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals

2016

UNLABELLED Essentials Sparse or outdated studies focus on thrombotic and bleeding risk in home parenteral nutrition (HPN). 236 HPN patients followed at a single center for a total of 684 patient-years were evaluated. Rates of venous thrombosis and major bleeding, and prevalence of vena cava syndrome are provided. Anticoagulants might reduce thrombosis risk, but population-specific safety concerns remain. SUMMARY Background Home parenteral nutrition (HPN) is necessary for patients with intestinal failure. Recurrent catheter-related thrombosis (CRT) is common, leading to infectious complications, pulmonary embolism, vascular access loss and intestinal transplantation. The efficacy and safety …

AdultMalemedicine.medical_specialtyCatheterization Central VenousSuperior Vena Cava SyndromeHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineThromboembolismmedicineHumans030212 general & internal medicineProportional Hazards ModelsRetrospective Studiesbusiness.industryHeparinHazard ratioAnticoagulantsRetrospective cohort studyThrombosisHematologyVenous ThromboembolismMiddle Agedmedicine.diseaseThrombosisThrombocytopeniaPulmonary embolismSurgeryTransplantationVenous thrombosisParenteral nutritionTreatment OutcomeFemalebusinessParenteral Nutrition HomePulmonary EmbolismCohort study
researchProduct

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

2017

Background and aims: Patients on parenteral nutrition for short bowel syndrome (SBS) have a high risk of thrombotic complications and are often treated with parenteral anticoagulation. Direct oral anticoagulants are absorbed proximally in the digestive tract and may represent alternative regimens in selected SBS patients. In our pilot study, we provided pharmacokinetics parameters of dabigatran etexilate and rivaroxaban in this setting and compared peak (Cmax), trough (Ctrough) concentrations, and areas-under-the-concentration-time-curve (AUC(0) (-) (t)) to reference values retrieved from phase I-III studies. Methods: We enrolled 6 adults with a remaining small bowel length <= 200 cm, norma…

AdultMaleShort Bowel SyndromeParenteral Nutritionmedicine.medical_specialtyCmax030204 cardiovascular system & hematologyGastroenterologyAntithrombinsDabigatran03 medical and health sciences0302 clinical medicineRivaroxabanPharmacokineticsInternal medicinemedicineHumans030212 general & internal medicineDosingAgedRivaroxabanbusiness.industryHematologyMiddle AgedShort bowel syndromemedicine.diseaseCrossover studyDabigatranParenteral nutritionAnesthesiaFemalebusinessmedicine.drugThrombosis Research
researchProduct